Antidote is a digital health company on a mission. Its aim is to accelerate breakthroughs in potentially life-saving treatments by bridging the gap between medical research and the people who need it.
In a world where 80% of clinical trials are delayed or closed due to lack of awareness, we use cutting-edge technology to match the right patients with the right trials. Antidote is helping medical researchers make progress faster – and offering new treatment options to patients in need.
In the media
13th February 2019
A Gaitherburg biotech is raising millions to treat nicotine-related diseases - and help smokers quit
Last week Antidote landed a contract with the National Cancer Institute to shepherd it through development, from manufacturing process development to filing an Investigational
9th February 2019
Antidote Therapeutics Enters into Agreement with National Cancer Institute
All program results and materials will be provided to Antidote Therapeutics for further development. The collaboration will be managed through NCIâ€™s Division of Cancer
29th January 2019
Octopus TitanVCT PLC Annual Financial Report -6-
Antidote Technologies Ltd Medical